Secondary Malignant Neoplasm

cancer family

Identifier: CI-CAN-00000346
Entity page: /cancer/secondary-malignant-neoplasm ↗
Edges: 9,230

Neighbours: 15 genes33 drugs10 trials
Drawn: 58 of 58 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Secondary Malignant Neoplasm approved for …APPROVED_FORderived57 of 57show fewer
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · Adenocarcinoma of the Breast	—	approved	Breast Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for	Fluorouracil

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

RET Mutation SelpercatinibFDA US 2020-05-086 active / 7 trials
Curatedlevel Asensitivity· support 3civicObservedRET altered in 2.6% (68 / 2,653 cases, largest of 2 cohorts)Regulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
RET M918T SelpercatinibFDA US 2020-05-086 active / 7 trials
Curatedlevel Asensitivity· support 2civicObservedRET altered in 2.6% (68 / 2,653 cases, largest of 2 cohorts)Regulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
EGFR G719A Afatinib3 active / 13 trials
Curatedlevel Asensitivity· support 1civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR L861Q Afatinib3 active / 13 trials
Curatedlevel Asensitivity· support 1civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR S768I Afatinib3 active / 13 trials
Curatedlevel Asensitivity· support 1civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
BRCA2 Loss-of-function OlaparibFDA US 2017-08-1726 active / 44 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 3.9% (104 / 2,653 cases, largest of 12 cohorts)Regulatoryapproved for Pancreatic Adenocarcinoma (2 approval records)context: Pancreatic Adenocarcinoma
BRCA1 Loss-of-function OlaparibFDA US 2017-08-1726 active / 44 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA1 altered in 2.9% (77 / 2,653 cases, largest of 3 cohorts)Regulatoryapproved for Pancreatic Adenocarcinoma (2 approval records)context: Pancreatic Adenocarcinoma
NRG1 Fusion Zenocutuzumab-zbco0 active / 0 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for NRG1 in this cancerno approval record in this cancercontext: Pancreatic Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Secondary Malignant Neoplasm altered in cohorts of …ALTERED_INderived15 of 1,062show all (up to 200)
← altered in cohorts of	COL7A1 450 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts	—	—	Clear Cell Renal Cell Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	GLB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PLXNB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATRIP 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CCDC51 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDC25A 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CELSR3 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FBXW12 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HHATL 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	IP6K2 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	NCKIPSD 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PFKFB4 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PRKAR2A 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PTH1R 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SCN5A 449 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts	—	—	Clear Cell Renal Cell Carcinoma	2	Observed	gdc	graph →

Secondary Malignant Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 331show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal antibody 346 trials (162 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	346	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 259 trials (92 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	259	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 220 trials (90 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	220	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 216 trials (87 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	216	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 189 trials (14 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	189	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 186 trials (83 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	186	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 178 trials (67 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	178	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 172 trials (48 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	172	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 155 trials (40 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	155	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 152 trials (66 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	152	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 114 trials (28 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	114	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 109 trials (32 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	109	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 107 trials (55 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 105 trials (37 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	105	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 101 trials (59 active) · roll-up of the cancer and its descendants	—	—	Secondary Malignant Neoplasm	101	Observed	clinicaltrials	graph →

Secondary Malignant Neoplasm studied in …STUDIED_INderived10 of 7,780show all (up to 200)
→ studied in	NCT00423306Phase 2 · completed A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02743741NA · completed Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 7,780 trials mapped (2,638 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03598257Phase 2 · active not recruiting Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Breast Inflammatory Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 7,780 trials mapped (2,638 active)	—	—	Collecting Duct Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03897543Phase 1/Phase 2 · completed ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma · condition mapped ALIAS · 7,780 trials mapped (2,638 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 7,780 trials mapped (2,638 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →